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Abstract
Background: Deletion of 3p is one of the most frequent genetic alterations in esophageal squamous cell carcinoma (ESCC),
suggesting the existence of one or more tumor suppressor genes (TSGs) within these regions. In this study, one TSG,
CACNA2D3 at 3p21.1, was characterized.
Methods: Expression of CACNA2D3 in ESCCs was tested by quantitative real-time PCR and tissue microarray. The
mechanism of CACNA2D3 downregulation was investigated by methylation-specific polymerase chain reaction (MS-PCR).
The tumor suppressive function of CACNA2D3 was characterized by both in vitro and in vivo tumorigenic assays, cell
migration and invasion assays.
Results: CACNA2D3 was frequently downregulated in ESCCs (24/48, 50%), which was significantly associated with promoter
methylation and allele loss (P,0.05). Tissue microarray result showed that downregulation of CACNA2D3 was detected in
(127/224, 56.7%) ESCCs, which was significantly associated with lymph node metastasis (P= 0.01), TNM staging (P= 0.003)
and poor outcome of ESCC patients (P,0.05). Functional studies demonstrated that CACNA2D3 could inhibit
tumorigenicity, cell motility and induce apoptosis. Mechanism study found that CACNA2D3 could arrest cell cycle at G1/
S checkpoint by increasing expressions of p21 and p53 and decreasing expression of CDK2. In addition, CACNA2D3 could
upregulate intracellular free cytosolic Ca2+ and subsequently induce apoptosis.
Conclusion: CACNA2D3 is a novel TSG responsible to the 3p21 deletion event and plays a critical suppressing role in the
development and progression of ESCC.
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Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most
common cancers with a very poor outcome in China [1]. ESCC is
characterized by its remarkable geographic distribution and high-
risk areas include Northern China, Northern Iran and South
Africa [2]. Although genetic alterations have been widely studied
in ESCC, the precise mechanisms underlying esophageal carci-
noma are poorly understood. Previous study in high-risk area
suggested that genetic susceptibility might play a role in the
pathogenesis of ESCC [3]. Like other solid tumors, the de-
velopment of ESCC is also believed as a multi-stage process caused
by the stepwise accumulation of genetic alterations. Comparative
genomic hybridization and loss of heterozygosity studies found
that deletion of 3p was one of the most frequent genetic alterations
in ESCC [4–5], suggesting the existence of one or more tumor
suppressor genes within these frequently deleted regions. Recently,
single-nucleotide polymorphism (SNP)-mass array was applied to
investigate the loss of heterozygosity at 3p in 100 primary ESCC
cases, leading to the identification of four commonly deleted
regions on 3p including 3p21 [6]. Two candidate TSGs, PLCD1 at
3p22 and PCAF at 3p24 have been characterized for their tumor
suppressing functions and mechanisms [7–8].
In the present study, another candidate TSG, CACNA2D3
(calcium channel, voltage dependent, alpha-2/delta subunit 3) at
3p21.1, was characterized for its tumor suppressive function and
mechanism. CACNA2D3 is an auxiliary member of the alpha-2/
delta subunit family of the voltage-dependent calcium channel
complex. Similar to CACNA2D2, it also regulates the influx of
calcium ions entering the cell upon membrane polarization [9].
There are four calcium channel voltage-dependent alpha-2/delta
subunit genes, CACNA2D1 to CACNA2D4 [10]. Frequent allele loss
of CACNA2D2 has been reported in lung, breast and other cancers
[11]. One report indicated that CACNA2D2 could mediate
apoptosis in non-small cell lung cancer cells [12]. Another study
found that promoter methylation of CACNA2D3 was frequently
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Figure 1. Downregulation of CACNA2D3 in ESCC tumor tissues. (A) qRT-PCR was used to compare CACNA2D3 expression between tumor (T)
and non-tumor (N) tissues in 48 ESCCs. The result was normalized by GAPDH. Fold change (log2N/T).1 (red line) was defined as ‘‘downregulation’’. (B)
Expression of CACNA2D3 in ESCC cell lines was detected by RT-PCR, compared to normal esophageal mucosa. (C) Representatives of CACNA2D3
expression (brown color) detected by IHC in a pair of ESCC tumor tissue and paired non-tumorous esophageal tissue (206objective). (D) Kaplan-Meier
analysis shows that CACNA2D3 downregulation is significantly associated with poor overall survival in 224 ESCC cases (P,0.05, Log-rank test).
doi:10.1371/journal.pone.0060027.g001
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detected in gastric cancer, which was associated with poor
prognosis of the disease [13]. Growing evidence showed that
Ca2+ signaling regulates diverse cellular processes such as
fertilization, development, proliferation, learning and memory,
and cell death [9]. Although CACNA2D3 has been associated with
the poor outcome of gastric cancer [13], the effect of CACNA2D3
on ESCC development is not clear. In the present study,
expression of CACNA2D3 in ESCC was detected in primary
ESCC and ESCC cell lines. Both in vitro and in vivo assays were
used to characterize the potential tumor suppressive function of
CACNA2D3.
Materials and Methods
Cell Lines and Primary Tumor Tissues
ESCC cell lines KYSE30, KYSE140, KYSE180, KYSE410,
and KYSE510 were obtained from DSMZ, the German Resource
Center for Biological Material [14]. Chinese ESCC cell line
HKESC1 was kindly provided by Professor G Srivastava [15].
The cells were confirmed by cytogenetics as human origin in 2009
[16]. Patients with ESCC were selected consecutively from the
surgical pathology archives of the Linzhou Cancer Hospital
(Henan, China). None of the patients in the study had received
preoperative radiation or chemotherapy. Tissue samples used in
the study were approved by the Committees for Ethical Review of
Research Involving Human Subjects in Zhengzhou University
(Zhengzhou, China). Written informed consents for the original
human work that produced the tissue samples were obtained.
Tissue Microarray and Immunohistochemistry
Tissue microarray containing 300 pairs of primary ESCC
(tumor and non-tumor tissues) cases was constructed as described
in previous report [16]. Corresponding matched non-tumor tissues
were obtained about 3 cm away from the tumor tissues (on
average). None of the patients in this study had received follow-up
radiation or chemotherapy. The age of patients ranged from 40–
80 years at the time of surgery (median age: 59 years) and the
male/female ratio was 1.3:1. Immunohistochemistry (IHC) was
performed using the standard streptavidin-biotin-peroxidase com-
plex method. A 1:100 diluted anti-CACNA2D3 (Novus Biologi-
cals, Littleton, CO) antibody was used for CACNA2D3 detection.
CACNA2D3 expression was compared between tumor and paired
non-tumor tissues.
Methylation Analysis
DNA extraction, bisulfate treatment, and MS-PCR was
performed as described previously [7]. Briefly, FastStart Taq
DNA Polymerase (Roche, IN) was utilized in the reaction, and the
cycle number was 40 which was within the linear amplification
range. The primers’ sequences of CACNA2D3 for methylation
analyses were: CAC-M-F: 59-TATTTCGAAATT-
TAGGGTGTTTTTC-39; CAC-M-R: 59-GATACTA CCAC-
CACGACTTAAACG-39; CAC-U-F: 59-
GTGGTGTGTTTGGAGTAGTAGAT ATT-39; CAC-U-R:
59-CCAAACTTAAACACAATAAATCACA-39.
LOH Detection in Tissue Samples and Fluorescence in
situ Hybridization (FISH)
Genomic DNA was extracted from tumor samples using
TIANamp genomic DNA kit (TIANGEN, China). SNP site
(rs589281) within CACNA2D3 gene was PCR amplified and
sequencing analyzed with primers (CAC-SNP-F1:59
TGTTGTGAT GATTAGGTGAG-39; CAC-SNP-R1:59
CTGTGGAGAATCACCTAATTC-39). The BAC probe was
labeled and FISH was performed as previously described [17].
Establishment of Cell Lines with Ectopic CACNA2D3
Expression
CACNA2D3 was cloned into expression vector pcDNA3.1(+) and
then transfected into KYSE30 and KYSE510 cells using
lipofectamineTM 2000 (Invitrogen, Calsbad, CA). Empty vector
was transfected into cell lines as negative controls. Stable colonies
were screened by G418 at 500 mg/ml.
RNA Extraction and Quantitative Real-time PCR (qRT-PCR)
RNA was extracted from tissues and cultured cells using Trizol
(Invitrogen, Calsbad, CA). Reverse transcription was performed
using SuperScript III (Invitrogen, Calsbad, CA). qRT-PCR was
processed using SYBR Green Supermix and ABI7900HT Fast
Real-Time PCR system (Applied Biosystems, Foster City, CA).
(CAC-Fq: 59-AGGGA TTCACGGTTATGCCTT-39; CAC-Rq:
59-GCCACACCTAAACCCTTTGTC-39). Triplicate assays were
done and values were normalized by the internal control (18S
rRNA or GAPDH). PCR products were subjected to dissociation
curve analysis to exclude amplification of nonspecific products.
Quantitative of the PCR data was processed using the DCT
method as described previously [18]. 2-fold was considered the
cutoff for ascertaining CACNA2D3 downregulation.
Antibodies and Reagents
Antibodies used: CACNA2D3 (Novus Biologicals, Littleton,
CO), GAPDH, p53, p21, Cyclin E, Cyclin A, CDK2, E-cadherin,
Table 1. Association between CACNA2D3 and
clinicopathologic features of ESCC.
Clinicopathologic features CACNA2D3 downregulation P-value
Age (years old) 0.686
#60 73/126 (57.9%)
.60 54/98 (55.1%)
Gender 0.786
Male 70/126 (55.6%)
Female 57/98 (58.2%)
Tumor location 0.273
Upper 23/48 (47.9%)
Middle 90/149 (60.4%)
Lower 14/27 (51.9%)
Differentiation 0.068
Well 15/26 (57.7%)
Moderate 93/147 (63.3%)
Poor 19/51 (37.3%)
Tumor invasion 0.409
T1+T2 13/27 (48.1%)
T3+T4 114/197 (57.9%)
Lymph nodes metastasis 0.01
N0 47/100 (47%)
N1 80/124 (64.5%)
TNM stage 0.003
I+IIa 34/79 (43.0%)
IIb+III+IV 93/145 (64.1%)
doi:10.1371/journal.pone.0060027.t001
CACNA2D3 in ESCC
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Caspase 3, and Caspase 8 (Cell Signaling Technology, Danvers,
MA). siRNA targeting CACNA2D3 was from Origene (MD).
In vitro Tumor Suppressive Assays
The effect of CACNA2D3 overexpression on cell proliferation
was assessed by determining cell growth and viability with the use
of CCK-8 (Dojindo, Japan). Foci formation assay and colony
formation in soft agar was performed as described [16]. Triplicate
independent assays were performed.
In vivo Tumor Suppressive Assay
The study was approved by Institutional Animal Care and Use
Committee of Cancer Cancer, Sun Yat-sen University. Animal
experiments were performed in compliance with the guidelines for
the Welfare of Experimental Animals in Cancer Center, Sun Yat-
sen University. The tumorigenicity of cells was assayed by tumor
formation in nude mice. CACNA2D3- and vector-transfected cells
(26106) cells were subcutaneously injected into the flanks of 4-
week-old male athymic BALB/c nu/nu mice (n = 5 for KYSE30
cells; n = 4 for KYSE510 cells), respectively. Tumor growth was
checked twice a week. Following euthanasia, tumors were excised,
fixed in 10% formalin and embedded in paraffin block for IHC
study.
Cell Migration and Invasion Assays
Transwell Permeable Support (24-well plate) (Corning Incor-
potated, NY) was used to assess the rate of cell migration. Briefly,
46104 cells in 100 ml of serum-free medium were added to the
upper chamber of the transwell insert. The lower chamber was
filled with 600 ml medium with 10% fetal bovine serum. After
22 hr of incubation at 37uC, penetrated cells to the lower surface
of the filter were fixed, stained with Crystal Violet, and counted
under a microscope. The assay was repeated three times. For
invasion assay, BioCoatTM MatrigelTM Invasion Chamber (24-
well plate) (Becton Dickinson and company, Franklin Lakes, NJ)
was used according to the manufacture’s protocol.
Cell Cycle Analysis
Tested cells (16106) were fixed in 70% ethanol, stained with
propidium iodide (Sigma-Aldrich, Germany) and DNA content
was analyzed by Cytomics FC 500 (BECKMAN COULTER,
Fullerton, CA). Cell cycle profile was then analyzed with Modfit
LT 2.0. Three independent assays were performed.
Measurement of Cytosolic Free Calcium
The intracellular free Ca2+ was measured by FACS with free-
Ca2+-sensitive Fluo3-AM green fluorescence probe (Sigma-Al-
drich, Germany). Cells were washed and incubated with 5 mM
probe diluted in medium without serum for 60 min at 37uC. Cells
were then washed and incubated with PBS for 30 min at 37uC in
the dark to allow cellular esterases to cleave the acetoxymethyl
group of Fluo 3-AM. Cells were trypsinized, washed and gently
resuspended in PBS. Fluorescence intensity was measured by
FACS analysis at an excitation wavelength of 488 nM and an
emission wavelength of 530 nM. Three independent experiments
were repeated.
Apoptosis Assay
Cells were treated with Staurosporine (STS, Sigma-Aldrich,
Germany) (0.25 mM for KYSE30, 0.1 mM for KYSE510), then
collected and analyzed 15 hr later. Apoptosis was detected by
Annexin-V-FLUOS Staining Kit (Roche, Germany) and in situ
Cell Death Detection Kit (Roche, Germany) according to the
manufacture’s protocol. Triplicate independent experiments were
performed.
Statistical Analysis
Statistical analyses were done using statistical software
package (Version 16.0; SPSS, Inc., USA). Pearson Chi-square
Table 2. Univariate and multivariate analysis of different prognostic variables in patients with ESCC.
Variables Univariable analysis* Multivariable analysis*
HR (95% CI) P HR (95% CI) P
Age 1.193 (0.915–1.554) 0.192
Gender 1.132 (0.867–1.477) 0.363
Tumor location 0.916 (0.730–1.151) 0.452
Tumor invasion
T1+T2 1.00
T3+T4 1.395 (0.937–2.076) 0.101
Differentiation
Poor 1.00
Well or moderate 0.682 (0.503–0.924) 0.014 0.688(0.504–0.938) 0.018
Lymph nodes metastasis
N0 1.00
N1 1.868 (1.428–2.442) ,0.001 1.716(1.227–2.402) 0.002
TNM stage
I+ II a 1.00
II b+III+IV 1.158 (1.044–1.286) 0.006 1.063(0.854–1.324) 0.583
CACNA2D3 downregulation 1.393 (0.994–1.953) 0.047 1.442(1.026–2.027) 0.054
*Cox regression model; HR, Hazards ratio; CI, confidence interval.
doi:10.1371/journal.pone.0060027.t002
CACNA2D3 in ESCC
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e60027
test was used to analyze the relationship between CACNA2D3
expression and clinic-pathological features. Survival curves were
generated according to the Kaplan-Meier method and statistical
analysis was performed by Log-rank test. The Cox proportional
hazards regression model was used to identify the independent
prognostic factors. Students’ t-test was used to analyze data
from function analysis, migration and invasion, TUNEL, and
in vivo tumor formation. P,0.05 was considered statistically
significant.
Results
CACNA2D3 is Frequently Downregulated in ESCC
Expression of CACNA2D3 was compared between tumor and
their paired non-tumor tissues in 48 ESCC patients by quantitative
real-time PCR. The result showed that the downregulation of
CACNA2D3 was detected in 24/48 (50%) of ESCC tumor tissues
compared with their paired non-tumor tissues (Fig. 1A). The
average expression level of CACNA2D3 was significantly reduced
in tumor tissues compared with their paired non-tumor tissues
(P,0.05). Downregulation of CACNA2D3 was also detected in 4
ESCC cell lines KYSE30, KYSE510, KYSE410 and HKESC1
(Fig. 1B).
Clinical Significance of CACNA2D3 Downregulation in
ESCC
Expression of CACNA2D3 in protein level was studied by
IHC using a tissue microarray containing 300 pairs (tumor and
non-tumor tissues) of primary ESCCs. Informative results were
obtained from 224 pairs ESCCs. Noninformative samples
Figure 2. Downregulation of CACNA2D3 is associated with promoter methylation and allele loss. (A) Representatives of CACNA2D3
expression (bottom) and promoter methylation status (upper) in primary ESCC cases. (B) Restoration of CACNA2D3 mRNA expression could be
observed in HKESC1 and KYSE180 after demethylating agent 5-AZA treatment. The promoter methylation status was also compared. (C)
Representative of allele loss at SNP site rs589281 in three ESCC tumors. The SNP site was indicated by red arrows. (D) Pattern of CACNA2D3
expression, promoter methylation and allele loss in 27 informative ESCC cases. (E) 2 centrimere signals (green, indicated by narrow arrows) and 1
CACNA2D3 signal (red, indicated by wide arrow) were detected in KYSE410 cells; Tumor cells with CACNA2D3 deletion are indicated by arrows
(1006objective).
doi:10.1371/journal.pone.0060027.g002
CACNA2D3 in ESCC
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60027
included lost or samples with too few tumor cells. Down-
regulation of CACNA2D3 was detected in 127/224 (56.7%)
informative ESCC tumor tissues compared with their paired
non-tumor tissues (Fig. 1C). Higher expression of CACNA2D3
in tumor tissue was observed in 13/224 (5.8%) of ESCCs.
Clinical association analysis demonstrated that downregulation
of CACNA2D3 was positively correlated with lymph node
metastasis (P=0.01) and advanced clinical staging (P=0.003,
Table 1). Univariate survival analysis revealed that down-
regulation of CACNA2D3 was significantly correlated with poor
Figure 3. CACNA2D3 inhibits tumorigenicity. (A) Detection of CACNA2D3 expression in CACNA2D3-transfected cells (30-CAC or 510-CAC)
compared with vector-transfected cells (30-Vec or 510-Vec). GAPDH was used as loading control. (B) Cell growth rate was significantly inhibited in
CACNA2D3-transfected cells compared with vector-transfected cells. (C) qRTPCR result of KYSE140 and cell growth rate was elevated in siRNA treated
cells. (D, E) Ability of focus formation was decreased by CACNA2D3 overexpression (D) and increased by silencing CACNA2D3 in cells (E). (F) Ability to
form colony in soft agar decreased significantly in CACNA2D3-transfected cells compared with vector cells. *, P,0.05.
doi:10.1371/journal.pone.0060027.g003
CACNA2D3 in ESCC
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overall survival (P,0.05, Table 2 and Fig. 1D). CACNA2D3
downregulation as well as other clinicopathologic features which
were significant in univariate analysis (e.g. tumor differentiation,
lymph nodes metastasis and TNM stage) were examined in
multivariate analysis (Table 2). The result showed that the
downregulation of CACNA2D3 was not an independent risk
factor for overall patient survival (P=0.054).
CACNA2D3 Downregulation is Associated with Promoter
Methylation and Allele Loss
As a putative mechanism for the downregulation of CACNA2D3
in ESCCs, methylation status of a candidate CpG-rich promoter
region was studied by methylation-specific PCR in 48 primary
ESCCs. Promoter methylation was detected in 28/48 (58.3%) of
tumor tissues (Fig. 2A). Downregulation of CACNA2D3 was
detected in 17/28 (60.7%) methylated cases, which is higher than
that in cases without promoter methylation (7/20, 35.0%). In
addition, expression of CACNA2D3 could be restored in KYSE180
and HKESC1 cells after the treatment of the demethylation agent
5-AZA-dC (Fig. 2B). These data suggested that downregulation of
CACNA2D3 was associated with hypermethylation in its pro-
moter region.
In our previous study, LOH at the SNP site rs589281 within
CACNA2D3 gene was detected in about 50% of primary ESCC
Figure 4. CACNA2D3 inhibits tumorigenicity in vivo and cell motility in vitro. (A) Tumor formation in nude mice was inhibited by CACNA2D3
in 30-CAC (left) and 510-CAC cells (right). Representatives of CACNA2D3 expression were detected by IHC in xenograft (206objective). (B, C)
Representative and summary of cell migration assay (B) and cell invasion assay (C) performed with CACNA2D3 forced expression cells or vector cells.
The results show that CACNA2D3 inhibits cell migration and cell invasion (206objective). **, P,0.001.
doi:10.1371/journal.pone.0060027.g004
CACNA2D3 in ESCC
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cases [6]. LOH at rs589281 site was also investigated in 48
ESCC samples and LOH was detected in 16/27 (59.3%) of
informative cases with heterozygosity at the SNP site (Fig. 2C).
Downregulation of CACNA2D3 was detected in 11/16 (68.8%)
LOH cases, which is higher than that in cases without allele loss
(4/11, 36.4%). We next investigated the correlation of
CACNA2D3 downregulation with its allelic loss and hypermethy-
lation in 27 informative cases. In 15 ESCCs with CACNA2D3
downregulation, inactivation of CACNA2D3 was significantly
associated with either methylation (n = 9) or LOH (n= 11), or
both methylation and LOH (n=6) (P,0.05, Fisher’s exact test,
Fig. 2D). To validate qRT-PCR result, Fluorescence in situ
hybridization (FISH) using BAC probe containing CACNA2D3
was performed to check the deletion of 3p21 in 3 ESCC cell
lines and 2 primary ESCC cases. The FISH result was
consistent with qRT-PCR result. Loss of CACNA2D3 allele
could be observed in 2 cell lines (KYSE410 and KYSE510) and
1 primary ESCC tumor with the downregulation of CAC-
NA2D3. (Fig. 2E).
Tumor Suppressive Function of CACNA2D3
To characterize its tumor suppressive function, CACNA2D3
was stably transfected into KYSE30 (30-CAC) and KYSE510
(510-CAC). Empty vector-transfected cells (30-Vec and 510-Vec)
were used as controls. Expression of CACNA2D3 was confirmed
by RT-PCR and western blotting (Fig. 3A). Cell growth assay
found that CACNA2D3 could significantly inhibit cell growth in
both tested cell lines (P,0.05, Fig. 3B). Similarly, CACNA2D3
could significantly reduce focus formation (P,0.05, Fig. 3D)
and colony formation in soft agar (P,0.05, Fig. 3F) in both
tested cell lines, compared with vector-transfected cells. Silenc-
ing CACNA2D3 could also reverse the results in KYSE140 and
KYSE180 cells (Fig. 3C, 3E).
To further explore the in vivo tumor suppressive ability of
CACNA2D3, tumor formation in nude mice was performed.
Empty vector- and CACNA2D3-transfected cells were injected
into the left and right flanks of nude mice, respectively. Twenty-
four days after injection, mice were sacrificed and xenografts
were excised for further analysis. The average weight of tumors
Figure 5. CACNA2D3 arrests cell cycle at G1/S checkpoint. (A) Representatives and summary of DNA content of cells detected by flow
cytometry. The results are expressed as mean6SD of three independent experiments. *, P,0.05, **, P,0.01. (B) Representatives and summary of DNA
content in CACNA2D3 silenced cells. Scramble siRNA was used as a control. **, P,0.01. (C, D, E) Expression of proteins was detected in CACNA2D3
overexpressed cells (C, E) and silenced cells (D). GAPDH and tubulin were used as loading controls.
doi:10.1371/journal.pone.0060027.g005
CACNA2D3 in ESCC
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induced by 30-CAC cells (0.16860.080 g) was significantly
decreased compared to the tumors induced by 30-Vec cells
(0.82560.072 g) (P,0.01, Fig. 4A). Similar result was also
observed in KYSE510 cells (P,0.01, Fig. 4A). The IHC result
showed that CACNA2D3 expression in CACNA2D3- transfected
cells was much stronger than the vector controls (Fig. 4A).
CACNA2D3 Inhibits Cell Motility
Cell migration assay showed that 56.76% and 76.19% decrease
in cells migrated through transwell were observed in the 30-CAC
and 510-CAC cells, respectively, compared with control cells
(Fig. 4B). Cell invasion assay found that cells invaded through
Matrigel were also significantly decreased in 30-CAC (91.03%) and
510-CAC (75.07%) cells, compared with that in 30-Vec and 510-
Vec cells, respectively (Fig. 4C).
CACNA2D3 Arrests Cell Cycle at G1/S Checkpoint
The cell cycle distribution between 30-CAC and 30-Vec cells
was compared by flow cytometry. The result found that 30-CAC
cells were arrested at G1/S checkpoint, manifested as an
accumulation of cells in G1 phase (average 56.4%) and a decrease
in S-phase cells (average 22.2%) compared to 30-Vec cells (G1
phase: average 36.9%; S-phase: average 37.2%) (Fig. 5A). Similar
G1/S checkpoint arrest was also detected in 510-CAC cells
(Fig. 5A). Silencing CACNA2D3 in KYSE140 cells caused
a decrease in G1 phase cells (140-siRNA: average 32.1%) and
increase in S phase cells (140-siRNA: average 44.1%) compared
with 140-scr control (G1: average 42.9%; S: average 29.2%).
(Fig. 5B). To investigate the potential mechanism of CACNA2D3 in
cell cycle arrest, expression of several key cell cycle regulators
including p21, p53, CDK2, Cyclin A and Cyclin E were tested by
western blotting. Increased expressions of p21 and p53, and
decreased expression of CDK2 were detected in 30-CAC cells
Figure 6. CACNA2D3 induces apoptosis. (A) Intracellular Ca2+ level was compared between CACNA2D3-transfected and vector-transfected cells by
FACS with Fluo 3-AM. A significant increase in fluorescence emission was observed in CACNA2D3-transfected cells compared with vector-transfected
cells. **, P,0.001. (B) Summary of TUNEL assay performed with CACNA2D3-transfected cells or vector-transfected cells treated with or without STS.
The results are expressed as mean6SD of three independent experiments. *, P,0.01. (C) Representative and summary of apoptotic index detected by
flow cytometry in CACNA2D3-transfected cells or vector-transfected cells treated with or without STS. The results are expressed as mean6SD of three
independent experiments. *, P,0.05. (D) Cleaved caspase-8 and caspase-3 were compared between CACNA2D3- and vector-transfected cells by
western blot analysis. Tubulin was used as a loading control.
doi:10.1371/journal.pone.0060027.g006
CACNA2D3 in ESCC
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compared with 30-Vec cells (Fig. 5C). Silencing endogenous
CACNA2D3 with siRNA in KYSE140 and KYSE180 cells also
decreased p21 and p53 (Fig. 5D). In addition, the expression of E-
cadherin was increased in CACNA2D3 overexpressed cells
compared with vector cells (Fig. 5E), silencing CACNA2D3 induced
the decrease of E-cadherin expression (Fig. 5D).
CACNA2D3 Upregulates Intracellular Free Cytosolic Ca2+
A previous study has reported that CACNA2D2 could elevate
intracellular Ca2+ level in non-small cell lung cancer cells [14]. In
the present study, intracellular Ca2+ level in the KYSE30 cells
after CACNA2D3 transfection was measured by FACS. A
significant increase in fluorescence emission was observed in 30-
CAC cells compared with 30-Vec cells (P,0.01) (Fig. 6A), in-
dicating that intracellular free cytosolic Ca2+ could be upregulated
by CACNA2D3. Similar results were also observed in 510-CAC cells
(Fig. 6A).
CACNA2D3 Induces Apoptosis
Since Ca2+ is able to mediate mitochondrial permeability
transition and trigger apoptosis [19], FACS and TUNEL assays
were used to compare apoptotic indexes between 30-CAC and 30-
Vec cells. The TUNEL results showed that the number of
apoptotic cells was similar between CACNA2D3-transfected and
vector-transfected cells (Fig. 6B). However, the number of
apoptotic cells was significantly increased in CACNA2D3-trans-
fected cells (P,0.05) after STS treatment, compared to empty
vector-transfected cells (Fig. 6B). Similar results were found by
using FACS assay. After STS treatment, the apoptotic index,
defined as the percentage of apoptotic cells (F2+F4), was
significantly higher in CACNA2D3 transfectants (P,0.05) com-
pared with empty vector-transfected cells (Fig. 6C). Western blot
analysis demonstrated that caspase-8 and caspase-3 were activated
by the detection of cleaved forms of caspase-8 and caspase-3
(Fig. 6D).
Discussion
In this study, we studied the downregulation of CACNA2D3 and
its tumor suppressive function and mechanism in ESCC.
CACNA2D3 is located at 3p21.1, a chromosomal region frequently
deleted in lung [20], esophageal [6,7], nasopharyngeal [21] and
renal cell [22] cancers, suggesting that the existence of tumor
suppressor gene(s) within the region that plays a critical role in the
development and progression in various solid malignancies
including ESCC. TSGs within 3p21 such as RAR-b, RASSF1A
[23], DLC1 [24] have been studied in ESCC. Here we described
the characterization of another candidate TSG CACNA2D3 at
3p21.
Downregulation of CACNA2D3 was detected in 50% and 56.7%
of primary ESCCs in mRNA and protein levels, respectively.
Further study found that downregulation of CACNA2D3 was
significantly correlated with allele loss and promoter hypermethy-
lation (P,0.05), indicating that DNA copy-number loss combined
with promoter methylation played an important role in CAC-
NA2D3 downregulation. We noted that 2/8 of ESCC cases with
both promoter methylation and allele loss retained expression of
CACNA2D3 (Fig. 2D). We believe that this issue could be either
caused by the heterogenicity of cancer or normal cell contamina-
tion (e.g. endothelial cells and lymphocytes). Actually, a small peak
of lost allele could be observed in all tumor samples. We also noted
that the promoter hypermethylation could be detected in 12/28
(42.8%) of methylation-positive ESCCs matched non-tumor
tissues, which might be promoted by local environment. For
example, Vasavi et al. found that patients with gastroesophageal
reflux disease showed a high degree of hMLH1 hypermethylation,
suggesting that local environment due to reflux might promote
hypermethylation [25]. We believe ‘‘epigenetic filed defect’’ exists,
which means slight methylation in the normal tissue but also a pre-
cancerous change. Because intraepitherial neoplasia is frequently
seen prior to ESCC, CACNA2D3 could be a feasible biomarker to
detect early change of the normal mucosa. Clinical significance
study indicated that CACNA2D3 could significantly inhibit lymph
nodes metastasis (P= 0.01) in ESCC. Kaplain-Meier analysis
showed that overall survival rate of ESCC patients decreased as
CACNA2D3 was downregulated in tumor tissues.
To explore the tumor suppressive function of CACNA2D3 in
ESCC, functional analysis of CACNA2D3 was performed by
ectopic expression of CACNA2D3 in ESCC cell lines KYSE30 and
KYSE510. The results found that CACNA2D3 could inhibit cell
growth, focus formation, colony formation in soft agar and tumor
formation in nude mice. Further study showed that CACNA2D3
could arrest cell cycle at G1/S checkpoint by upregulating p53
and p21 expression and downregulating CDK2 expression. In
addition, an elevated intracellular Ca2+ level was detected when
CACNA2D3 was introduced into cells, which was similar to the
results of CACNA2D3 in gastric cancer cells [13] and CACNA2D2
in non-small cell lung cancer cells [12]. It has been reported that
Ca2+ influx could promote activation of the transcription factor
CREB (cAMP response element binding protein) leading to the
cell cycle arrest in G1 phase via transactivation of p53/p21
signaling pathways [26]. Moreover, Ca2+ regulates the cell cycle
through various signaling pathways including Ras [27], PTEN
[28] and Rb [29] signaling pathways. It has been found that Ca2+
could mediate mitochondrial permeability transition and trigger
apoptosis [19]. In this study, we found that CACNA2D3 could
significantly increase apoptotic index after STS treatment
(P,0.05).
E-cadherin is the prototypic cadherin which is often lost
partially or completely in epithelial tumors when they progress
toward malignancy [30]. In this process, neoplastic cells have lost
many of the epithelial characteristics and exhibit a highly invasive
pattern [31]. In diffuse gastric cancer, E-cadherin is inactivated
mainly through LOH, somatic mutations and promoter hyper-
methylation [32]. It has been reported that calcium signals
regulate cell to cell adhesion through recruitment of cadherins and
b-catenin into intracellular junction in fibroblasts [33]. Studies also
found that reducing E-cadherin could induce disruption of the E-
cadherin adhesion complex and correlated with elevated cell
migration and invasion of different carcinoma cells [34]. In this
study, we found that CACNA2D3 could effectively inhibit cell
motility in KYSE30 and KYSE510 cells, which might be
associated with the upregulation of E-cadherin caused by the
influx of Ca2+. In summary, our data indicate for the first time that
downregulation of CACNA2D3 is frequently detected in ESCC and
associated with poor prognosis. Both promoter hypermethylation
and allele loss contribute to the downregulation. We also
demonstrate that CACNA2D3 has strong tumor suppressive
function through the cell cycle arrest and induction of apoptosis.
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